Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04469075 · ClinicalTrials.gov registry record · Phase 2

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

A Phase 2 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
48
Enrollment target
8
Study locations

NCT04469075: Active Phase 2 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04469075 is a Phase 2 study of Glioblastoma and Recurrent Glioblastoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 48 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (56% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04469075, a Phase 2 study of Glioblastoma and Recurrent Glioblastoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
48 participants
Enrollment target
8
Study locations

Study Summary

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

Primary Outcome

device-related skin adverse events by investigator assessment.

Conditions Studied

Glioblastoma Recurrent Glioblastoma Skin Toxicity

Interventions

  • DRUG Triamcinolone Acetonide
  • DRUG Clindamycin Phosphate

Study Locations (8)

New York

  • Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities) - Hauppauge
  • Memorial Sloan Kettering Cancer Center - New York
  • Columbia University - New York

Illinois

  • Northwestern University - Evanston

Massachusetts

  • Tufts Medical Center - Boston

Missouri

  • Washington University School of Medicine - St Louis

New Jersey

  • Hackensack Meridian Health - Hackensack

Ohio

  • University of Cincinnati Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2020-07-09
Est. Completion 2026-07
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04469075 still lists

NCT04469075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (56% lower).

The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.

NCT04469075 lists 8 locations in 6 states (New York, Illinois, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT04469075 about?

NCT04469075 is a clinical study titled "Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields". The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

What is the current status of trial NCT04469075?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-07-09. Estimated completion is 2026-07.

What conditions does trial NCT04469075 study?

This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Skin Toxicity.

What interventions are being tested in trial NCT04469075?

The interventions under investigation include: Triamcinolone Acetonide (DRUG), Clindamycin Phosphate (DRUG).

Who is sponsoring clinical trial NCT04469075?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04469075 being conducted?

This trial has 8 study locations across Illinois, Massachusetts, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04469075's enrollment target sits among peer trials

48 90th of 199 higher than 106 of 199 other Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04469075, the US trial registry maintained by the National Library of Medicine. NCT04469075 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.